Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis-Reference-Cited by-同舟云学术

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Published:2022-01 Issue:1 Volume:17 Page:103-115
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Planchard David,Besse Benjamin,Groen Harry J.M.,Hashemi Sayed M.S.,Mazieres Julien,Kim Tae Min,Quoix Elisabeth,Souquet Pierre-Jean,Barlesi Fabrice,Baik Christina,Villaruz Liza C.,Kelly Ronan J.,Zhang Shirong,Tan Monique,Gasal Eduard,Santarpia Libero,Johnson Bruce E.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference46 articles.

1. National Comprehensive Cancer Network. Non-small cell lung cancer, version 6. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 29, 2020.

2. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016

3. Personalized diagnostic workflows: the next wave of precision medicine in NSCLC;Dagogo-Jack;J Thorac Oncol,2020

4. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA,2019

5. Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer;Tsang;Cold Spring Harb Mol Case Stud,2019

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study;Future Oncology;2024-09-03

2. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma;Cell Reports Medicine;2024-08

3. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC;Lung Cancer;2024-08

4. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer;Frontiers in Oncology;2024-07-16

5. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives;Frontiers in Oncology;2024-07-11